What German experts expect from individualized medicine: problems of uncertainty and future complication in physician–patient interaction
- 1 June 2012
- journal article
- research article
- Published by SAGE Publications in Clinical Ethics
- Vol. 7 (2) , 86-93
Abstract
‘Individualized medicine’ is an emerging paradigm in clinical life science research. We conducted a socio-empirical interview study in a leading German clinical research group, aiming at implementing ‘individualized medicine’ of colorectal cancer. The goal was to investigate moral and social issues related to physician–patient interaction and clinical care, and to identify the points raised, supported and rejected by the physicians and researchers. Up to now there has been only limited insight into how experts dedicated to individualized medicine view its problems. Interviews with researchers and clinicians ( n= 19) were based on a prestructured questionnaire. The content analysis revealed a broad spectrum of opinions. Major findings were (a) disappointments with the limits of the current therapy regimen and clinical practice; (b) problematic impacts on physician–patient relationship; and (c) an informed consent procedure which is mainly based on paternalistic assumptions. According to our analysis, major problems will be uncertainties related to the biomarker's sensitivity and specificity, and the identification of ‘non-responders’. However, the findings also indicate that experts expect evidence-based medicine to replace decisions based on gut feeling or hierarchical structures.Keywords
This publication has 29 references indexed in Scilit:
- Study newsletters, community and ethics advisory boards, and focus group discussions provide ongoing feedback for a large biobankAmerican Journal of Medical Genetics Part A, 2011
- Contribution of biomarkers to personalized medicineBreast Cancer Research, 2010
- Offering Individual Genetic Research Results: Context MattersScience Translational Medicine, 2010
- Individualisierte Medizin – Potenziale und HandlungsbedarfZeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen, 2010
- Clinical Trial Designs for Evaluating the Medical Utility of Prognostic and Predictive Biomarkers in OncologyPersonalized Medicine, 2009
- Healthcare professionals’ and researchers’ understanding of cancer genetics activities: a qualitative interview study: Table 1Journal of Medical Ethics, 2009
- Analysis of the MammaPrint Breast Cancer Assay in a Predominantly Postmenopausal CohortClinical Cancer Research, 2008
- Genetic Testing for Late-Onset Diseases: Effect of Disease Controllability, Test Predictivity, and Gender on the Decision to Take the TestGenetic Testing, 2007
- ‘At the point at which you can do something about it, then it becomes more relevant’: Informed consent in the pharmacogenetic clinicSocial Science & Medicine, 2005
- Managing health risks: junior doctors' views of risk and decision makingJournal of Health Organization and Management, 2004